Why the study?
CKD is an independent risk factor for cognitive impairment, and complex medication regimens in these patients frequently include drugs linked to negative cognitive effects.
Do medications such as psychotropic agents, anticholinergics, and opioids cause cognitive impairment in patients with chronic kidney disease?
Do medications such as psychotropic agents, anticholinergics, and opioids cause cognitive impairment in patients with chronic kidney disease?
This review highlights the importance of considering the cognitive side effects of common medications, such as psychotropics and anticholinergics, when prescribing for patients with chronic kidney disease.
May warrant medication review in CKD for cognitive risks; leaves open interventional trials before practice change.
There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.
No takes yet. Share an insight, caveat, or question.
Hafez et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: